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Abstract
Object: Glioblastoma is a highly malignant brain tumor, for which standard treatment 
consists of surgery, radiotherapy, and chemotherapy. Increasing extent of tumor 
resection (EOTR) is associated with prolonged survival. Intraoperative magnetic 
resonance imaging (iMRI) is used to increase EOTR, based on contrast enhanced 
MR images. The correlation between intraoperative contrast enhancement and 
tumor has not been studied systematically.
Methods: For this prospective cohort study, we recruited 10 patients with a 
supratentorial brain tumor suspect for a glioblastoma. After initial resection, a 
0.15 Tesla iMRI scan was made and neuronavigation‑guided biopsies were taken 
from the border of the resection cavity. Scores for gadolinium‑based contrast 
enhancement on iMRI and for tissue characteristics in histological slides of the 
biopsies were used to calculate correlations (expressed in Kendall’s tau).
Results: A total of 39 biopsy samples was available for further analysis. Contrast 
enhancement was significantly correlated with World Health Organization (WHO) 
grade (tau 0.50), vascular changes (tau 0.53), necrosis (tau 0.49), and increased 
cellularity (tau 0.26). Specificity of enhancement patterns scored as “thick linear” 
and “tumor‑like” for detection of (high grade) tumor was 1, but decreased to circa 
0.75 if “thin linear” enhancement was included. Sensitivity for both enhancement 
patterns varied around 0.39‑0.48 and 0.61‑0.70, respectively.
Conclusions: Presence of intraoperative contrast enhancement is a good predictor 
for presence of tumor, but absence of contrast enhancement is a bad predictor for 
absence of tumor. The use of gadolinium‑based contrast enhancement on iMRI 
to maximize glioblastoma resection should be evaluated against other methods 
to increase resection, like new contrast agents, other imaging modalities, and 
“functional neurooncology” – an approach to achieve surgical resection guided by 
functional rather than oncological‑anatomical boundaries.
Key Words: Glioblastoma, image guided surgery, intraoperative magnetic 
resonance imaging, neurooncology, neuropathology
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INTRODUCTION
Glioblastoma is a highly malignant brain tumor that often 
shows extensive infiltrative growth in the surrounding 
brain parenchyma. Standard treatment consists of surgery, 
radiotherapy, and chemotherapy, leading to a median 
survival of 14.6 months.[29,28] Although the role of 
surgery is still under debate, mounting evidence suggests 
that increased extent of tumor resection (EOTR) is 
associated with prolonged survival.[23] Intraoperative 
magnetic resonance imaging (iMRI) is a technique that 
can help to increase EOTR, comparable to the use of 
5‑aminolaevulinic acid (5‑ALA).[26]
The added value of iMRI in increasing EOTR for 
glioblastoma is based on visualizing remaining contrast 
enhancement on T1‑weighted scans at the border of the 
resection cavity. This contrast enhancement is supposed 
to indicate residual tumor, which can be resected in the 
same procedure. In a few studies the additionally resected 
tissue was sent separately for histological analysis, leading 
to varying reports on tumor presence.[25,20,16] However, 
due to the infiltrative nature of a glioblastoma, tumor 
cells are often present outside the contrast enhancing 
area.[5,1] If contrast enhancement on T1‑weighted iMRI 
is to be used as a marker for high grade glioma, then 
contrast enhancing tissue should exhibit more high grade 
tumor characteristics than non (contrast) enhancing 
tissue. Serial stereotactic biopsies have been performed 
on preoperative computed tomography (CT) and MRI, 
demonstrating tumor cells outside the contrast enhancing 
area.[9] To our knowledge, such studies have not been 
performed systematically on iMRI, in which contrast 
agent is administered after tumor resection (i.e., after 
possible iatrogenic damage to the blood–brain barrier). 
Therefore, histologic results correlated to preoperative 
imaging might not correlate to iMRI.
This is the first study that systematically compares 
contrast enhancement on iMRI with histopathological 
characteristics in glioblastoma. The study objective is 
to determine to what extent contrast enhancement on 
T1‑weighted iMRI can be used as a marker for presence 
of (high grade) glioma, and therefore as a valid indicator 
to assess EOTR.
MATERIALS AND METHODS
The study protocol is registered at ClinicalTrials.gov 
under number NCT00780819 and has been approved by 
the institutional ethics research board.
Patient selection
For this prospective cohort study, we recruited 
10 patients with a supratentorial brain tumor suspect 
for a glioblastoma. We determined the number of 
patients to be included based on consensus in the study 
committee. Inclusion criteria were: Indication for tumor 
resection, minimum age of 18 years, World Health 
Organization (WHO) Performance Scale 2 or better, 
American Society of Anaesthesiologists (ASA) class 3 
or better, understanding of the Dutch language, and 
informed consent. Exclusion criteria were: Recurrent 
tumor, multiple tumor locations, prior radiotherapy on 
the skull, and prior chemotherapy.
Study endpoints
Primary endpoint of this study was the correlation 
between contrast enhancement at the border of 
the resection cavity on T1‑weighted iMRI and 
presence of high grade tumor according to the WHO 
classification.[15] Secondary endpoints of this study were: 
Correlation between contrast enhancement at the border 
of the resection cavity on T1‑weighted MRI and other 
histopathologial tissue characteristics, postoperative 
clinical condition, and survival.
Surgical procedure
All study participants were operated by a 
neurosurgeon (OS, MtLP, or HvS) sufficiently 
experienced with the 0.15 Tesla iMRI system used in our 
hospital (PoleStar N20 with Stealth Station extension; 
Medtronic Navigation, Louisville, CO). After patient 
installation in the headclamp, a contrast enhanced 
preoperative (high‑field strength) MRI was loaded for 
surgical planning and initial neuronavigation. Before 
incision, a nonenhanced iMRI scan was made as a 
baseline scan that intraoperatively acquired scans could 
be compared with.
During tumor resection, resected tissue was sent for 
standard histopathological analysis. As soon as the 
neurosurgeon considered the intended tumor resection to be 
complete, T1‑weighted iMRI scans were acquired using the 
so‑called “T1 7 min 4 mm”‑protocol in axial orientation: 
First a nonenhanced scan, then a contrast enhanced 
scan using gadopentetate dimeglumine (Magnevist; 
Bayer‑Schering Pharma AG, Berlin, Germany). Contrast 
dose was 0.4 ml/kg (0.2 mmol/kg) – a so‑called 
“double‑dose” – provided no renal failure was present. 
The contrast enhanced scan was made immediately after 
intravenous contrast administration.
After scanning neuronavigation was continued on the 
contrast enhanced iMRI scan, which was imported 
in the Stealth Station neuronavigation system. In all 
directions where gross total resection was intended, 
neuronavigation‑guided biopsies were taken at the 
border of the resection cavity. A screen capture from 
the neuronavigation system was saved for each biopsy 
to relate contrast enhancement with histopathology. 
Each biopsy was sent separately for histopathological 
analysis, labeled with a number corresponding to the 
screen capture. After taking the biopsies, surgery was 
continued to resect any contrast enhancement in a 
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direction where gross total resection was intended. 
Scanning was repeated if this goal was considered to be 
achieved, and additional biopsies were taken if safely 
possible. Contrast administration was only repeated 
if the previous iMRI scan was performed more than 2 
hours back, in a dose of 0.2 mmol/kg (0.1 mmol/kg) – a 
“single‑dose” – provided no renal failure was present.
Perioperative procedure
Preoperative and postoperative MRI scans were made with 
the Intera 1.5 Tesla MRI system (Release 11.1; Philips, 
Best, The Netherlands). Preoperative neuronavigation 
scans were contrast‑enhanced T1‑weighted volume 
scans (isovoxel 1 mm, gap thickness 0 mm). Postoperative 
multiple sequences were acquired in a standardized fashion, 
including contrast enhanced T1‑weighted sequences. 
Gadopentetate dimeglumine was used as a contrast agent 
in a dose of 0.2 ml/kg (0.1 mmol/kg) provided no renal 
failure was present.
All preoperative and postoperative scans were performed 
within 72 hours before and after surgery, respectively.
WHO Performance Scale was measured the day before 
surgery, and one week after surgery.
Determination of contrast enhancement
The screen captures from the biopsy locations were 
independently reviewed by a neurosurgeon and a senior 
resident in neurosurgery (HvS and PK). Both have ample 
experience in interpreting PoleStar images. Contrast 
enhancement was scored according to a four‑tier 
classification [Table 1] described by Ekinci et al.: 
None, thin linear, thick linear, and (suspected) residual 
tumor.[4] Screen captures that were scored differently by 
the reviewers were reviewed together to obtain consensus.
Determination of histopathological characteristics
The biopsy tissue samples were independently reviewed 
by two experienced neuropathologists (PW and ML), 
blinded for corresponding contrast enhancement. 
Histopathological characteristics were scored for 10 
parameters (most of these in a semiquantitative fashion): 
Amount of tissue, quality of tissue, preexistent tissue, 
increased cellularity, tumor presence, mitoses, vascular 
changes, necrosis, inflammation, and WHO grade in the 
sample. To each individual biopsy specimen in which 
tumor was present a WHO grade was assigned according 
to the WHO 2007 classification of tumors of the central 
nervous system[15]: Grade II = no mitotic activity, 
no necrosis and no florid microvascular proliferation 
found; grade III = mitotic activity present, but absence 
of necrosis and florid microvascular proliferation; 
grade IV: Presence of necrosis and/or florid microvascular 
proliferation. The values for each parameter are 
displayed in Table 2. The so‑called “Tier 1 items” to 
be reported according to the “Biospecimen reporting for 
improved study quality” (BRISQ) recommendations are 
displayed in Table 3.[17] Tissue samples that were scored 
different by the neuropathologists were reviewed together 
to obtain consensus.
Statistics
Interobserver agreement for contrast enhancement, WHO 
classification and histopathological parameters were 
Table 1: Ekinci classification for scoring contrast 
enhancement
Description Definition
None No visible contrast enhancement
Thin linear Resembles normal dural enhancement (<5 mm)
Thick linear Thicker than typical dural enhancement (5-10 mm)
Suspected residual 
tumor
>10 mm in any imaging plane
Table 2: Classification for histopathological 
characteristics
Parameter Values
Preexistent tissue White matter, gray matter, combination, 
indeterminate
WHO grade No WHO grade: Nonneoplastic (normal or 
reactive changes); WHO grade II: Low grade 
diffuse astrocytoma; WHO grade III: Anaplastic 
astrocytoma; WHO grade IV: Glioblastoma
Vascular changes No apparent, vasodilatation, hypertrophic 
endothelium, florid microvascular proliferation
Necrosis Absent, indeterminate, focal, local, extensive
Mitoses No, sparse, moderate, frequent
Increased cellularity No apparent, limited, moderate, marked
Table 3:Biospecimen reporting for improved study quality 
Tier 1 items
Data element Value
Biospecimen type Perifocal brain tumor parenchyma
Anatomic site Cerebrum
Disease status of patients WHO performance scale≤2
Clinical characteristics of 
patients
Neurological deficit dependent on tumor 
location
Vital state of patients Alive
Clinical diagnosis of 
patients
Supratentorial intra-axial brain tumor, 
suspect for high grade glioma
Pathology diagnosis Glioblastoma 
Collection mechanism Tumor forceps
Type of stabilization Saline 0.9% solution
Type of long-term 
preservation
Formalin-fixed, paraffin embedded
Constitution of preservative 10% neutral-buffered formalin
Storage temperature Room temperature
Storage duration 6-18 months
Relocation temperature Room temperature (after embedding in 
paraffin)
Composition assessment 
and selection
Scored as “adequate” regarding “amount 
of tissue” and “quality of tissue”
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expressed as kappa‑squared values, calculated with an 
in‑house made application. Correlation between contrast 
enhancement and histopathological parameters was 
expressed as Kendall’s tau with a one‑tailed significance, 
calculated in PASW Statistics version 18.0.3 for Mac (IBM 
Corporation, Armonk, NY). Further analysis consisted 
of creating crosstables to calculate sensitivity, specificity, 
positive predictive value (PPV), negative predictive 
value (NPV), positive likelihood ratio (LR+), and negative 
likelihood ratio (LR‑) for contrast enhancement in relation 
to WHO grade. Two definitions were used for presence of 
contrast enhancement: “Thick linear + tumor‑like” versus 
“thin linear + thick linear + tumor‑like”. In addition, two 
definitions were used for presence of tumor: “Grade III 
+ grade IV” versus “grade II + grade III + grade IV”. 
Calculations were performed with Microsoft Excel for Mac 
version 2011 (Microsoft, Redmond, WA), as well as the 
graphical representation of the interobserver agreement.
RESULTS
Patient characteristics
Table 4 shows relevant characteristics of the 
10 participants included in this study, including 
information on tumor location, and preoperative and 
postoperative WHO Performance Status (WPS). Patients 
were recruited between October 2008 and July 2009, 
and follow‑up lasted until all patients died. Age varied 
between 46 and 71 years, with a mean of 59.7 ± 9.0 years. 
Six patients were male and four patients were female. 
The main tumor mass was located in the left versus right 
cerebral hemisphere in six and four patients, respectively, 
and the tumor was most frequently located in the frontal 
lobe (n = 4), followed by the temporal lobe (n = 3), 
parietal lobe (n = 2), and occipital lobe (n = 1).
All patients but one were administered a double‑dose 
of contrast agent, the remaining patient received a 
single‑dose because of preexisting renal dysfunction, which 
was, however, not a contraindication for gadolinium‑based 
contrast agent. Standard histopathological examination of 
the resected tumor revealed glioblastoma as the clinical 
diagnosis for all patients. The total number of study 
biopsy samples of all patients was 42. The number of 
biopsy samples per patient varied between 2 and 8, with 
a mean of 4.2 ± 1.9 samples. In two patients, biopsy 
samples were taken in two different phases during 
surgery. In those cases the delay between the first dose 
of contrast administration and the second iMR scan 
was 115 and 90 minutes, respectively, and according 
to our protocol no new dose of contrast agent was 
administered before the second iMR scan. Preoperative 
WPS varied between 0 and 2, with a mean of 0.7 ± 0.7. 
Postoperative WPS varied between 0 and 2, with a mean 
of 0.9 ± 0.6. Two patients (BZS02 and BZS03) suffered 
from transient neurological deficit postoperatively, one 
due to a supplementory motor area (SMA) syndrome and 
another due to postoperative hemorrhage. Both patients 
recovered within a few days from WPS 3 ‑ 4 to WPS 1. 
All patients received the standard treatment consisting 
of radiotherapy and chemotherapy postoperatively.[29,28] 
Postoperative survival varied between 40 and 721 days, 
with a mean of 350 ± 215 days (median 372 days). Of 
note, the patient with the shortest survival (BZS05) 
opted for euthanasia. Postoperative survival is displayed 
as a Kaplan–Meier curve in Figure 1.
Interobserver agreement
A total of 42 samples were available for further analysis, 
39 of these were scored as “adequate” both on “amount 
of tissue” and “quality of tissue”. Table 5 shows the 
results for both observers for contrast enhancement 
and tissue characteristics for these 39 samples. 
Interobserver agreement is calculated for each parameter 
and expressed as kappa‑squared with 95% confidence 
intervals in Figure 2. For all biopsies, tumor parameters 
that were scored differently by both observers were 
Table 4: Study demographics
Code Sex, 
age (y)
Tumor 
location
WPS 
pre/post
Contrast 
dose*
Second 
scan delay
NoS NoATS
BZS01 M, 51 L frontal 0/0 Double N/A 5 5
BZS02 M, 60 R frontal 0/1 Double 115 min 5+1 4+1
BZS03 M, 62 L temporal 0/1 Single N/A 2 2
BZS04 F, 69 L frontal 1/1 Double 90 min 5+3 5+3
BZS05 M, 46 L temporal 1/1 Double N/A 3 2
BZS06 F, 61 L parietal 1/1 Double N/A 5 4
BZS07 F, 47 R temporal 2/2 Double N/A 3 3
BZS08 M, 71 R occipital 1/1 Double N/A 4 3
BZS09 F, 69 L frontal 1/1 Double N/A 4 3
BZS10 M, 61 R parietal 0/0 Double N/A 2 1
F: Female, L: Left, M: Male, min: Minutes, N/A: Not applicable,  
NoATS: Number of Adequate Tumor Samples, NoS: Number of Samples, post: 
Postoperative, pre: Preoperative, R: Right, WPS: WHO Performance Status, y: Years,  
*A single dose of contrast is 0.1 mmol/kg, a double dose is 0.2 mmol/kg Figure 1: Kaplan–Meier curve displaying postoperative survival
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Table 5a: Crosstable for “contrast enhancement”
None Thin linear Thick linear Residual tumor
None 20 1 0 0
Thin linear 2 5 2 4
Thick linear 0 1 2 3
Residual tumor 0 0 0 2
Table 5b: Crosstable for “WHO grade”
Normal/NT RC Grade II Grade III Grade IV
Normal/NT 6 1 0 0 0
RC 1 0 0 0 0
Grade II 0 1 4 0 0
Grade III 0 0 3 0 4
Grade IV 0 0 2 2 12
Abbreviations: NT: No Tumor, RC: Reactive changes
Table 5c: Crosstable for “preexistent tissue”
Gray+white White Gray Indeterminate
Gray+white 9 2 1 1
White 3 4 0 2
Gray 5 1 0 1
Indeterminate 0 1 0 12
Table 5d: Crosstable for “increased cellularity”
Extreme Marked Moderate Limited No apparent
Extreme 0 2 0 1 0
Marked 0 6 9 1 0
Moderate 0 2 4 3 0
Limited 0 0 0 1 0
No apparent 0 0 0 4 9
Table 5e: Crosstable for “vascular changes”
No apparent Vasodilatation +HT +Florid MVP
No apparent 10 1 0 0
Vasodilatation 7 2 1 0
+HT 2 1 3 4
+Florid MVP 0 0 1 7
Abbreviations: HT: Hypertrophic endothelium, MVP: Microvascular proliferation Table 5f: Crosstable for “necrosis”
Extensive Local Focal Indeterminate Absent
Extensive 4 0 0 0 1
Local 2 1 0 0 0
Focal 0 1 0 0 1
Indeterminate 0 0 0 2 3
Absent 0 0 3 1 23
Table 5g: Crosstable for “mitoses”
Frequent Moderate Sparse No
Frequent 1 2 3 0
Moderate 1 3 0 0
Sparse 0 0 4 4
No 0 0 4 20
Figure 2: Interobserver agreement for each tumor parameter expressed in kappa-squared (CI = confidence interval)
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Table 6: Correlation coefficients for “contrast 
enhancement” related to other tumor parameters
Tumor parameter Kendall’s tau Significance* NoS
WHO grade 0.50 <0.01 36
Vascular changes 0.53 <0.01 38
Necrosis 0.49 <0.01 39
Mitoses 0.09 0.27 39
Increased cellularity 0.26 0.03 39
NoS: Number of Samples (available for statistical analysis per tumor parameter),  
*The 1‑tailed significance is expressed in a P value
Table 7a: Crosstable with “WHO grade”
Normal/NT Grade II Grade III Grade IV
No enhancement 6 4 3 4
Thin linear 2 1 2 3
Thick linear 0 0 1 5
Suspected tumor 0 0 0 5
Abbreviations: NT: No Tumor
Table 7b: Crosstable with “increased cellularity”
No apparent Limited Moderate Marked
No enhancement 5 4 6 4
Thin linear 2 1 3 2
Thick linear 1 0 3 3
Suspected tumor 0 0 3 2
Table 7c: Crosstable with “vascular changes”
No apparent Vasodilatation +HT +Florid MVP
No enhancement 11 2 4 2
Thin linear 2 3 2 1
Thick linear 0 2 1 3
Suspected tumor 0 0 0 5
Abbreviations: HT: Hypertrophic endothelium, MVP: Microvascular proliferation
Table 7d: Crosstable with “necrosis”
Absent Indeterminate Focal Local Extensive
No enhancement 17 0 2 0 0
Thin linear 4 1 1 0 2
Thick linear 1 1 0 2 3
Suspected tumor 2 0 2 0 1
scored again, now by both observers simultaneously. 
This consensus‑based final value was chosen for further 
analysis.
Correlation between contrast enhancement and 
tumor
Of the 39 adequate biopsy samples, 3 had an uncertain 
diagnosis regarding WHO grade. Correlations between 
contrast enhancement and tumor were calculated using 
the remaining 36 samples and displayed in Table 6. Four 
tumor parameters demonstrated a significant correlation 
with contrast enhancement: WHO grade, vascular 
changes, necrosis and increased cellularity. In particular 
the first three demonstrated highly significant but only 
moderately strong correlation, with Kendall’s tau values 
around 0.50. The parameter “tumor presence” was found 
to have no additional value over the information obtained 
by combining grade II, III and IV lesions in the parameter 
“WHO grade”. Furthermore, substantial interobserver 
variation for the parameter “inflammation” prevented 
meaningful analysis of this parameter. Therefore, the 
parameters “tumor presence” and “inflammation” are not 
further incorporated in the tables and results.
Subgroup analysis
To gain more insight in the type of correlation, crosstables 
are created to relate the values for contrast enhancement 
with the respective values for each tumor parameter. The 
results are presented in Table 7, and used to calculate 
sensitivity, specificity, PPV, NPV, LR+ and LR‑. Table 8 
shows these values for the correlation between “contrast 
enhancement” and “WHO grade” using two definitions 
for each parameter (see also “Materials and Methods” 
section). If “contrast enhancement” is defined as “thick 
linear” plus “tumor‑like” then the PPV is 1 and the LR+ 
goes to infinity, regardless of tumor definition (only high 
grade components versus low grade components as well). 
Sensitivity is 0.48 if only high grade components are 
included, and 0.39 if low grade components are included 
as well. If “contrast enhancement” is defined including 
“thin linear” enhancement, then specificity falls to circa 
0.75 and sensitivity rises to 0.70 (for only high grade 
components) or 0.61 (including low grade components). 
Figure 3 contains a web diagram illustrating the 
sensitivity and specificity of contrast enhancement (using 
two definitions) for all significantly correlated tumor 
parameters.
Sensitivity, NPV and LR‑all vary around 0.50. This means 
that half of the histologically confirmed “tumor samples” 
show contrast enhancement, and half do not. Moreover, 
half of the contrast enhancing samples are classified as 
“tumor”, and half are not.
DISCUSSION
The goal of a “gross total resection”, or “complete 
resection of enhancing tumor” (CRET)[30] of a 
glioblastoma is to resect the contrast enhancing part 
as visualized on T1‑weighted MRI. However, tumor 
cells are known to be present outside this contrast 
enhancing area,[5,1] and recent studies comparing contrast 
enhancement on T1‑weighted MRI with diffusion 
weighted MRI and Positron Emission Tomography have 
demonstrated a considerable nonoverlap between tumor 
delineation using these different techniques.[7,21] Our 
study compares contrast enhancement at the border 
of the resection cavity with histopathological tumor 
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Table 8: Subgroup analysis correlating “contrast enhancement” and “WHO grade” using two definitions per parameter
Contrast definition Thick linear+ 
tumor‑like
Thick linear+ 
tumor‑like
Thin linear+thick linear+ 
tumor‑like
Thin linear+thick linear+ 
tumor‑like
Tumor definition* III+IV II+III+IV III+IV II+III+IV
Sensitivity 0.48 0.39 0.70 0.61
Specificity 1.00 1.00 0.77 0.75
PPV 1.00 1.00 0.84 0.89
NPV 0.52 0.32 0.59 0.35
LR+ ∞ ∞ 3.01 2.43
LR- 0.52 0.61 0.40 0.52
LR‑ : Negative Likelihood Ratio, LR+ : Positive Likelihood Ratio, NPV: Negative Predictive Value, PPV: Positive Predictive Value, thick linear: Thick Linear enhancement, thin linear: 
Thin Linear enhancement, tumor‑like: Suspected residual tumor enhancement, *Tumor definition is expressed in “WHO grade” as explained in the methods section
Figure 3:  Web diagram demonstrating sensitivity and specificity of contrast enhancement (using two definitions) for all significantly 
correlated tumor parameters
characteristics to determine to what extent contrast 
enhancement correlates with tumor.
The classification we used for contrast enhancement is 
derived from Ekinci et al.[4] They describe that thin linear 
“dural like” enhancement leads to tumor regrowth in 
only 1 out of 16 cases, whereas thick linear enhancement 
leads to tumor regrowth in all cases, in particular when 
nodular (tumor‑like) components are present. The 
study by Ekinci studied postoperative 1.5 Tesla MRI 
using 0.1‑0.2 mmol/kg gadolinium‑DTPA. Intraoperative 
contrast enhancement may differ due to iatrogenic 
manipulation and direct damage to the blood‑brain 
barrier. Therefore we used two definitions for “contrast 
enhancement” in our study, both with and without thin 
linear enhancement.
Four histological parameters are significantly correlated 
with contrast enhancement at the border of the resection 
cavity: WHO grade, vascular changes, necrosis, and 
increased cellularity. Of note, these histological features 
are interrelated. For instance, diffusely increased cellularity 
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in a brain biopsy sample is an important indicator for the 
presence of a diffuse glioma, and the presence of necrosis 
and/or florid microvascular proliferation are the histological 
hallmarks of high malignancy grade in a diffuse glioma. 
Furthermore, the correlation itself is relatively weak, with 
Kendall’s tau values of 0.49‑0.53 for WHO grade, vascular 
changes and necrosis, and a value of 0.26 for increased 
cellularity. As the Kendall’s tau is a nonparametric test 
that describes correlation but provides no detailed 
information on the kind of correlation, we calculated 
sensitivity and specificity for the relation between contrast 
enhancement and tumor presence, using two definitions 
for each. Our results are consistent with Ekinci et al. for 
thick linear + tumor‑like enhancement: Specificity is 1, 
regardless whether tumor definition includes what we 
defined as “WHO grade II”. Importantly, all patients in our 
study had a histologically proven glioblastoma. With the 
histological designation WHO grade II to biopsy samples 
of these patients we refer to samples in which the tumor 
lacked histological features of high grade malignancy in that 
particular (small) specimen. Of note, glioblastomas often 
show areas (e.g., in the diffuse infiltrative, peripheral parts) 
in which such histological features of high grade malignancy 
are lacking, but this does not necessarily mean that the 
glioblastoma originated from a less malignant precursor 
lesion. Likewise, PPV and LR+ are maximal for thick linear 
+ tumor‑like enhancement regardless of tumor definition. 
Sensitivity is rather low: 0.48 when including only high 
grade tumor components, and 0.39 when including grade II 
components as well. Comparable conclusions can be drawn 
for NPV and LR‑. If we expand our definition of contrast 
enhancement to include thin linear enhancing tissue, 
specificity falls to circa 0.75 regardless of tumor definition, 
PPV varies around 0.84‑0.89 and LR+ varies around 2.4‑
3.0. Sensitivity rises to 0.70 for only high grade components 
and 0.61 if grade II components are included. NPV and 
LR‑ also improve slightly.
Translating these numbers into practical conclusions, 
one can say that presence of evident contrast 
enhancement (thick linear + tumor‑like) always refers to 
presence of tumor, regardless of whether histologically less 
malignant components are included. This is an interesting 
finding because “iatrogenic damage” to the blood–brain 
barrier is thought to cause false‑positive intraoperative 
contrast enhancement. Our results demonstrate that this 
is not the case for thick linear enhancement, but it might 
be an explanation for the lower specificity when thin linear 
enhancement is included. Note that we refrained from 
contrast administration before incision to prevent residual 
contrast enhancement after tumor resection, which possibly 
can cause contrast enhancement in nontumorous tissue.[6]
Absence of tumor is always correlated with absence of 
thick linear enhancement and tumor‑like enhancement. 
Unfortunately, our study shows that absence of contrast 
enhancement is not useful for predicting absence of 
tumor. In our study 41‑68% of the biopsy samples 
showed tumor despite absence of contrast enhancement, 
depending on definition of enhancement (thin linear + 
thick linear + tumor‑like versus thick linear + tumor‑like).
Strengths and limitations
To the best of our knowledge this is the first report with a 
prospective systematic comparison of intraoperative contrast 
enhancement and histopathological tumor characteristics, 
with comparison of biopsies from contrast enhancing and 
nonenhancing tissue as a particular added value. This is 
in contrast with previously published work.[16,20,25] Another 
strength is that both neuropathologists, evaluating the 
histological parameters in the biopsies, were blinded for the 
pattern of contrast enhancement.
As far as we know, no validated scoring systems exist 
for contrast enhancement or for assessment of the 
histopathological characteristics of glial tumors as 
assessed in the present study. The scale we used for 
grading contrast enhancement has been published in 
an evaluation of tumor regrowth on postoperative MRI, 
and the scale we used for grading histopathological 
characteristics has been developed by two experienced 
neuropathologists (PW, ML). To increase reliability we 
assessed interobserver agreement for all measurements, 
and found this to be satisfactory except for the parameter 
“inflammatory changes”. Consensus‑based outcomes were 
used for further analysis, thereby decreasing subjectivity 
and variation in measurements.
The sample number of 10 patients may be relatively low, 
but the number of biopsies that was adequate for further 
analysis (n = 39) was satisfactory. The number of biopsy 
samples per patient varied because (as also described 
in the inclusion criteria) the neurosurgeon only took 
biopsies in those directions where it was considered to be 
safely possible.
Magnetic field strength is related to spatial resolution 
of the MR images and capacity of obtaining other 
imaging modalities (e.g. diffusion weighted imaging, 
MR spectroscopy). A limitation of this study is that our 
results cannot automatically be transferred to high‑field 
strength iMRI. However, we do not expect that using a 
high‑field strength iMRI would result in a substantially 
different outcome as this would only increase spatial 
resolution. Of course, the use of additional imaging 
modalities could be of added value.
We used gadopentetate dimeglumine for this study, and 
gadolinium‑based contrast agents are commonly used 
for (intraoperative) MRI. An interesting alternative for 
neurosurgeons might be the use of so‑called “ultrasmall 
particles of iron oxide” (USPIO)‑based agents, which 
have been tested on iMRI as well.[18,19,8] These might be 
less susceptible for iatrogenic damage of the blood–brain 
barrier, and could offer better correlations between thin 
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linear contrast enhancement and tumor. Of note, in 
case of thick linear and tumor‑like enhancement we 
found no indications for imaging artefacts (in particular 
false‑positive contrast enhancement) related to damage 
of the blood–brain barrier. Specificity for high grade 
tumor in this pattern of contrast enhancement equals 1.
Our study is limited to assessment of remaining 
tumor using iMRI. A recent study investigated 
the use of 5‑ALA as a marker for representative 
stereotactic biopsy samples in several types of tumor, 
and found better values compared with our study for 
specificity (1.00) and sensitivity (0.69) in case of strong 
5‑ALA fluorescence.[32] Another study used 5‑ALA to 
differentiate between necrosis, (fluorescent) “tumor 
cells”, and (nonfluorescent) “margin cells”. They found 
that margin cells do not possess a ‘stem‑cell molecular 
signature’ but retain tumor‑initiating ability in vivo.[22] 
This finding is important, as it contradicts the belief that 
especially these margin cells are highly tumorigenic. To 
what extent 5‑ALA fluorescence correlates with contrast 
enhancement on iMRI (and therefore – indirectly – with 
tumorigenicity of cells at the resection cavity, is currently 
being investigated (Senft et al., personal communication 
September 2012). The consequences of these findings on 
surgical strategy regarding EOTR remain to be seen.
Implications for the future
Contrast enhancement on low‑field strength iMRI at 
the border of the glioblastoma resection cavity has 
a high specificity but low sensitivity for high grade 
tumor. Absence of contrast enhancement is unreliable 
to assess absence of tumor, and from that perspective 
the rationale for CRET becomes debatable. Especially 
in glioma surgery complication avoidance is of critical 
importance. Increasing sensitivity of tumor detection to 
increase EOTR may be undesirable if a corresponding 
lower specificity is associated with a higher incidence 
of (and/or more severe) postoperative neurological deficit. 
Furthermore, the definition of “tumor” is being discussed 
to include more than the contrast enhancing part,[31,30] 
and this may change the philosophy about maximizing 
tumor resection. There is class 1 evidence that iMRI 
offers increased EOTR compared with a population of 
high grade glioma patients that were operated with or 
without conventional neuronavigation.[26] In a posthoc 
exploratory analysis Senft et al. found no difference 
between both treatment arms in the control group, which 
is consistent with the Willems et al. study.[33,26] Based on 
other literature there is, at best, class 2 evidence that 
iMRI‑guided surgery is more effective than conventional 
neuronavigation‑guided surgery in increasing EOTR, 
enhancing quality of life, or prolonging survival after 
glioblastoma resection.[10]
Recently, the concept of ‘functional neurooncology’ was 
introduced by Duffau et al. in low grade gliomas as a 
method to achieve optimal surgical resection guided 
by functional rather than by oncological‑anatomical 
boundaries.[2,3] This approach does not suffer from 
imaging‑related limitations. If increased EOTR is 
associated with prolonged survival, the “functional 
neurooncology” approach might also be an alternative in 
high grade glioma surgery to determine resection borders 
compared with an imaging‑based approach.
CONCLUSIONS
Our present study on glioblastomas shows that evident 
contrast enhancement (thick linear + tumor‑like) as 
detected on iMRI always reflects presence of high 
grade tumor and may thus be used as a parameter to 
increase EOTR. Furthermore, absence of tumor is always 
correlated with absence of such contrast enhancement. 
Unfortunately absence of contrast enhancement and 
presence of thin linear enhancement on iMRI is not 
useful for predicting absence of tumor. Obviously, 
diffuse gliomas including glioblastomas are neoplasms 
that cannot be cured surgically. An (arbitrary) minimally 
required resection threshold to improve survival, like 
the widely cited 98% as described by Lacroix et al.[13] is 
debatable, and a valid method to measure this threshold 
still has to be established.[30,11,24,12,27,14] The use of 5‑ALA 
or a “functional neurooncology” approach may be 
interesting alternatives for high grade glioma surgery 
using gadolinium‑based contrast agents to increase 
EOTR safely.
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